Products Categories
CAS No.: | 99294-93-6 |
---|---|
Name: | Zolpidem tartrate |
Molecular Structure: | |
Formula: | 2(C19H21N3O).C4H6O6 |
Molecular Weight: | 764.86 |
Synonyms: | N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide 2,3-dihydroxybutanedioate (2:1);(2R,3R)-2,3-Dihydroxybutandis?ure--N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamid(1:2);Bilcam;Cymerion;Dalparan;Durnit;Eudorm;Ivadal;Myslee;N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide L-(+)-Tartrate (2:1);N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide 2,3-dihydroxybutanedioate (2:1);Niotal;SL 800750-23N;Stilnoct;Stilnox;Stimox;Sumenan;Zolpidem L-(+)-hemitartrate; |
EINECS: | 200-659-6 |
Melting Point: | 196oC /Zolpidem/ |
Appearance: | White to off-white crystalline powder |
Hazard Symbols: | Xi |
Risk Codes: | 36/37/38 |
Safety: | 26-36 |
PSA: | 152.67000 |
LogP: | 1.12620 |
The Zolpidem tartrate, with the CAS registry number 99294-93-6, has the systematic name of N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide 2,3-dihydroxybutanedioate (2:1). It belongs to the following product categories: Active Pharmaceutical Ingredients; Hypnotic; Zolpidem. And the molecular formula of this chemical is 2(C19H21N3O).C4H6O6.
Physical properties of Zolpidem tartrate are: (1)ACD/LogP: 3.07; (2)# of Rule of 5 Violations: 0; (3)#H bond acceptors: 4; (4)#H bond donors: 0; (5)#Freely Rotating Bonds: 3; (6)Polar Surface Area: 37.61 Å2.
You should be cautious while dealing with this chemical. It irritates to eyes, respiratory system and skin. Therefore, you had better take the following instructions: Wear suitable protective clothing, rinse immediately with plenty of water and seek medical advice.
You can still convert the following datas into molecular structure:
(1)SMILES: O=C(O)[C@H](O)[C@@H](O)C(=O)O.O=C(N(C)C)Cc1c(nc2ccc(cn12)C)c3ccc(cc3)C.O=C(N(C)C)Cc1c(nc2ccc(cn12)C)c3ccc(cc3)C
(2)InChI: InChI=1/2C19H21N3O.C4H6O6/c2*1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19;5-1(3(7)8)2(6)4(9)10/h2*5-10,12H,11H2,1-4H3;1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1
(3)InChIKey: VXRDAMSNTXUHFX-CEAXSRTFBG
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
child | TDLo | oral | 500ug/kg (.5mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | Journal of Toxicology, Clinical Toxicology. Vol. 35, Pg. 453, 1997. |
child | TDLo | oral | 5mg/kg (5mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP | Journal of Toxicology, Clinical Toxicology. Vol. 35, Pg. 453, 1997. |
human | TDLo | oral | 857ug/kg (.857mg/kg) | VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP | Journal of Toxicology, Clinical Toxicology. Vol. 32, Pg. 391, 1994. |
man | TDLo | oral | 143ug/kg (.143mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) | Journal of Clinical Pyschopharmacology. Vol. 14, Pg. 150, 1994. |
man | TDLo | oral | 4286ug/kg (4.286mg/kg) | BEHAVIORAL: COMA LUNGS, THORAX, OR RESPIRATION: BRONCHIOLAR CONSTRICTION VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | Human & Experimental Toxicology. Vol. 9, Pg. 105, 1990. |
mouse | LD50 | oral | 695mg/kg (695mg/kg) | Journal of Toxicology, Clinical Toxicology. Vol. 32, Pg. 391, 1994. | |
rat | LD50 | oral | 2700mg/kg (2700mg/kg) | Journal of Toxicology, Clinical Toxicology. Vol. 32, Pg. 391, 1994. | |
women | LDLo | oral | 6mg/kg (6mg/kg) | BLOOD: OTHER CHANGES | Forensic Science International. Vol. 78, Pg. 165, 1996. |
women | TDLo | oral | 200ug/kg (.2mg/kg) | SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | Lancet. Vol. 342, Pg. 443, 1993. |